logo
logo
AI Products 
Leaderboard Community🔥 Earn points

Wound Gel Market: Industry Demand, Analysis and Future Trends 2033

avatar
Sara James
collect
0
collect
0
collect
3
Wound Gel Market: Industry Demand, Analysis and Future Trends 2033

The global wound gel market size was valued at USD 6.05 billion in 2024 and is projected to reach USD 9.68 billion by 2033, growing at a CAGR of 5.37% from 2025 to 2033. The demand for wound gel is rising owing to the increasing number of surgical cases and the growing burden of wounds.

The rising number of surgical procedures worldwide is a significant driver for expanding the wound gels market. Surgical interventions often result in acute wounds that require effective post-operative care to minimize infection risk and promote faster healing. Advanced wound care products, particularly wound gels, are increasingly preferred due to their ability to maintain a moist wound environment, support autolytic debridement, and accelerate tissue regeneration. According to data published in the BMC Surgery journal in 2025, approximately 313 million surgical procedures are performed globally annually. This substantial volume underscores the growing demand for reliable and effective wound care solutions, reinforcing the critical role of wound gels in the post-surgical healing process.

List of Key Players in the Wound Gel Market

Medline Industries, LP.

Coloplast Ltd

Mölnlycke Health Care AB

Solventum

Convatec Inc.

Smith+Nephew

B. Braun SE

DermaRite Industries, LLC.

Integra LifeSciences Corporation

Axio Biosolutions Private Limited

Sanara MedTech Inc

Request a free sample copy or view report summary: Wound Gel Market

Wound Gel Market Report Highlights

The dressings segment dominated the wound gel industry in 2024, driven by continuous innovation in advanced materials such as hydrogel, gelling fiber, and specialty formulations like honey and silicone gel dressings.

The silver (Ag+) segment held the largest market share in 2024 within the antimicrobial properties segment, demonstrating its leading role in advanced wound care. It is also anticipated to grow fastest over the forecast period.

The chronic wounds segment dominated the market in 2024, capturing the largest share of 55.29%. This dominance is attributed to the high prevalence and significant healthcare burden associated with chronic wounds.

The offline segment held the largest market share in 2024. This dominance is primarily attributed to the widespread availability of wound gel products through hospitals, pharmacies, and medical supply stores, where healthcare professionals often guide product selection.

The hospital segment dominated the market in 2024, accounting for the largest share of 41.52%. This dominance is due to the high volume of patients requiring advanced wound care for acute and chronic conditions.

Wound Gel Market Segmentation

Grand View Research has segmented the global wound gel market report based on product, antimicrobial properties, application, mode of purchase, distribution channel, end use, and region:

Product Outlook (Revenue, USD Million, 2021 - 2033)

Dressings

  • Hydrogel dressing
  • Gelling fiber dressings
  • Others

Gels

Antimicrobial Properties Outlook (Revenue, USD Million, 2021 - 2033)

Silver (Ag+)

Non-Silver

Mode of Purchase Outlook (Revenue, USD Million, 2021 - 2033)

Prescription

Non-prescription

Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

Offline

Online

Application Outlook (Revenue, USD Million, 2021 - 2033)

Chronic Wounds

  • Diabetic Foot Ulcers (DFUs)
  • Pressure Ulcers

- Stage 1

- Stage 2

- Stage 3

- Stage 4

  • Leg Ulcers

Acute Wounds

  • Surgical Incisions
  • Burns

1st Degree

2nd Degree

3rd Degree

  • Lacerations, Abrasions

End Use Outlook (Revenue, USD Million, 2021-2033)

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgery Centers
  • Homecare Settings
  • Long-Term Care Facilities
  • Others

Regional Outlook (Revenue, USD Million, 2021-2033)

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

South Korea

Australia

Thailand

Latin America

Brazil

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Recent Developments

  • In March 2025, SolasCure announced the enrollment of the first patient in its upcoming Phase II clinical trial to advance the development of the Aurase Wound Gel. This marks a significant milestone in the company’s efforts to evaluate the safety and efficacy of the gel in promoting wound healing. The trial is designed to gather critical data supporting further clinical development and potential regulatory approval of this innovative treatment.
  • In March 2025, Mölnlycke Health Care completed the acquisition of the manufacturer of Granudacyn. Granudacyn includes solutions and gels designed explicitly for wound cleansing, irrigation, and moisturizing across various wound types. This strategic acquisition strengthens Mölnlycke’s portfolio, enhancing its capabilities to deliver comprehensive and effective solutions for wound care and infection prevention.
collect
0
collect
0
collect
3
avatar
Sara James